Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study

Welf Prager,1 Eva K Bee,2 Isabel Havermann,1 Ina Zschocke3 1Dermatologikum Hamburg, Hamburg, Germany; 2Praxis für Dermatologie, Hautarztpraxis Stengel and Bee, Münster, Germany; 3SCIderm, Hamburg, Germany Background: IncobotulinumtoxinA (Bocouture®) is free from complexing...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Prager W, Bee EK, Havermann I, Zschocke I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	aesthetics frown lines botulinumtoxinA Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/932974b03b53414ebb1a1743670cf9a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:932974b03b53414ebb1a1743670cf9a7
record_format	dspace
spelling	oai:doaj.org-article:932974b03b53414ebb1a1743670cf9a72021-12-02T00:34:39ZOnset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study1178-1998https://doaj.org/article/932974b03b53414ebb1a1743670cf9a72013-04-01T00:00:00Zhttps://www.dovepress.com/onset-longevity-and-patient-satisfaction-with-incobotulinumtoxina-for--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Welf Prager,1 Eva K Bee,2 Isabel Havermann,1 Ina Zschocke3 1Dermatologikum Hamburg, Hamburg, Germany; 2Praxis für Dermatologie, Hautarztpraxis Stengel and Bee, Münster, Germany; 3SCIderm, Hamburg, Germany Background: IncobotulinumtoxinA (Bocouture®) is free from complexing proteins and effective for treating glabellar frown lines. Purpose: To determine the efficacy, onset, and duration of action of incobotulinumtoxinA for the treatment of glabellar frown lines. Patients and methods: In this single-arm, prospective, proof-of-concept study, 23 patients were treated with 25 U incobotulinumtoxinA, equally split between five injection sites in the glabella. Severity of glabellar frown lines was rated by an independent rater from standardized photographs using the validated Merz 5-point scale at several visits over 5 months following treatment. To assess patient satisfaction, patients completed a questionnaire before and 2 weeks after treatment. Results: The percentage of responders at maximum frown 2-4 days after treatment was 95.2% and 85.0% when responders were defined as patients with ≥1-point and ≥2-point improvement on the 5-point scale compared with baseline, respectively. At this time point, 84% of the maximum effect had occurred. The responder rate at maximum frown, according to both definitions, was 100% for at least the next two visits (days 8 ± 1 and 14 ± 2). At all visits, the change from baseline in the mean glabellar frown-line score at maximum frown was statistically significant, with on average an almost 1-point improvement from baseline 5 months after treatment. Conclusion: IncobotulinumtoxinA is an effective and well-tolerated treatment for glabellar frown lines, with a rapid onset of action and a long duration of effect lasting for more than 5 months. Keywords: aesthetics, frown lines, botulinum toxin APrager WBee EKHavermann IZschocke IDove Medical Pressarticleaestheticsfrown linesbotulinumtoxinAGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 449-456 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	aesthetics frown lines botulinumtoxinA Geriatrics RC952-954.6
spellingShingle	aesthetics frown lines botulinumtoxinA Geriatrics RC952-954.6 Prager W Bee EK Havermann I Zschocke I Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
description	Welf Prager,1 Eva K Bee,2 Isabel Havermann,1 Ina Zschocke3 1Dermatologikum Hamburg, Hamburg, Germany; 2Praxis für Dermatologie, Hautarztpraxis Stengel and Bee, Münster, Germany; 3SCIderm, Hamburg, Germany Background: IncobotulinumtoxinA (Bocouture®) is free from complexing proteins and effective for treating glabellar frown lines. Purpose: To determine the efficacy, onset, and duration of action of incobotulinumtoxinA for the treatment of glabellar frown lines. Patients and methods: In this single-arm, prospective, proof-of-concept study, 23 patients were treated with 25 U incobotulinumtoxinA, equally split between five injection sites in the glabella. Severity of glabellar frown lines was rated by an independent rater from standardized photographs using the validated Merz 5-point scale at several visits over 5 months following treatment. To assess patient satisfaction, patients completed a questionnaire before and 2 weeks after treatment. Results: The percentage of responders at maximum frown 2-4 days after treatment was 95.2% and 85.0% when responders were defined as patients with ≥1-point and ≥2-point improvement on the 5-point scale compared with baseline, respectively. At this time point, 84% of the maximum effect had occurred. The responder rate at maximum frown, according to both definitions, was 100% for at least the next two visits (days 8 ± 1 and 14 ± 2). At all visits, the change from baseline in the mean glabellar frown-line score at maximum frown was statistically significant, with on average an almost 1-point improvement from baseline 5 months after treatment. Conclusion: IncobotulinumtoxinA is an effective and well-tolerated treatment for glabellar frown lines, with a rapid onset of action and a long duration of effect lasting for more than 5 months. Keywords: aesthetics, frown lines, botulinum toxin A
format	article
author	Prager W Bee EK Havermann I Zschocke I
author_facet	Prager W Bee EK Havermann I Zschocke I
author_sort	Prager W
title	Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
title_short	Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
title_full	Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
title_fullStr	Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
title_full_unstemmed	Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
title_sort	onset, longevity, and patient satisfaction with incobotulinumtoxina for the treatment of glabellar frown lines: a single-arm, prospective clinical study
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/932974b03b53414ebb1a1743670cf9a7
work_keys_str_mv	AT pragerw onsetlongevityandpatientsatisfactionwithincobotulinumtoxinaforthetreatmentofglabellarfrownlinesasinglearmprospectiveclinicalstudy AT beeek onsetlongevityandpatientsatisfactionwithincobotulinumtoxinaforthetreatmentofglabellarfrownlinesasinglearmprospectiveclinicalstudy AT havermanni onsetlongevityandpatientsatisfactionwithincobotulinumtoxinaforthetreatmentofglabellarfrownlinesasinglearmprospectiveclinicalstudy AT zschockei onsetlongevityandpatientsatisfactionwithincobotulinumtoxinaforthetreatmentofglabellarfrownlinesasinglearmprospectiveclinicalstudy
_version_	1718403632491134976

Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study

Ejemplares similares